News

Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.

The China National Medical Products Administration has accepted an application for gilteritinib for the treatment of adult patients with FLT3 mutation–positive acute myeloid leukemia.

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

STP705 met the primary efficacy end point in an ongoing phase II study of patients with cutaneous squamous cell carcinoma in situ.

The NCCN has published guidelines for ensuring that patients with cancer, care providers, and staff are kept as safe as possible during the COVID-19 crisis.

An increased proportion of Indigenous American genetic ancestry may be linked with a higher incidence of HER2-positive breast cancer.

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the impact of the COVID-19 outbreak on Hong Kong and explained how the implementation of early preventive safety measures may have contributed to the low incidence rate.

A supplemental Biologics License Application has been filed with the FDA for avelumab for the frontline maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.

The FDA has approved the combination of encorafenib and cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.

The investigational RAF inhibitor lifirafenib demonstrated antitumor activity in patients with melanoma and other solid tumors.

Michael Wang, MD, discusses the implications of the ZUMA-2 trial for patients with relapsed/refractory mantle cell lymphoma and other targeted therapies on the horizon.

Florida Cancer Specialists & Research Institute recently launched telehealth services across all Florida Cancer Specialists & Research Institute sites statewide, allowing patients continued and convenient access to care, while mitigating the impact and spread of COVID-19.

AV-GBM-1 showed early promise in an interim overall survival analysis of an ongoing phase II trial in patients with newly diagnosed glioblastoma.

Rana R. McKay, MD, discusses the evolving role of cabozantinib in the renal cell carcinoma treatment paradigm and the research being done examining novel combinations.

When the first case of coronavirus disease 2019 was diagnosed in Washington on January 20, 2020 clinicians at Seattle Cancer Care Alliance decided to act expeditiously and unhesitatingly to minimize disease spread.

The FDA has granted a priority review designation to nivolumab plus ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.

Treatment with paxalisib, an investigational small molecule inhibitor of the PI3K/AKT/mTOR pathway, was associated with a positive overall survival signal in patients with glioblastoma.

The FDA has granted the PD-1 inhibitor balstilimab a Fast Track Designation for the treatment of patients with cervical cancer.

Andre Goy, MD, MS, discusses the utility of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

The FDA has granted a fast track designation to sacituzumab govitecan for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.

Selinexor, an FDA-approved drug for the treatment of patients with relapsed/refractory multiple myeloma, is being evaluated in a global randomized clinical trial as a potential treatment for hospitalized patients with severe COVID-19.

The addition of acalabrutinib (Calquence) to venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia, eliciting deep and durable responses.

Joshua M. Bauml, MD, discusses challenges in providing care to patients with lung cancer in light of the COVID-19 pandemic and ongoing efforts to reduce unnecessary exposure to the virus.